Table of Contents
About 6.9 million Americans over 65 are living with Alzheimer’s disease, a figure projected to roughly double by 2060. Parkinson’s affects close to a million people in the U.S. Multiple sclerosis touches an estimated 2.9 million worldwide. Those numbers only start to make sense once you understand what these conditions share — misfolded proteins, dying neurons, decades of quiet damage — and where each one stubbornly refuses to behave like the others.
Here are the seven neurodegenerative diseases you’re most likely to encounter in a neurology clinic, in roughly the order of how often they appear.
What “Neurodegenerative” Actually Means
Neurons mostly don’t regenerate. When they die, the tissue around them changes shape to compensate, which is why symptoms can lag years behind the underlying disease. A person with Parkinson’s has typically already lost 50–70% of the dopamine-producing cells in the substantia nigra by the time a tremor shows up.
The unifying feature is a protein that folds into the wrong shape and spreads. Amyloid-beta and tau in Alzheimer’s. Alpha-synuclein in Parkinson’s and Lewy body dementia. TDP-43 in most ALS cases. Huntingtin in Huntington’s disease. Prion protein in Creutzfeldt-Jakob disease. Different proteins, different brain regions, wildly different timelines.
1. Alzheimer’s Disease
Alzheimer’s accounts for 60–80% of dementia cases and is the best-known of the group. It starts in the hippocampus, which is why short-term memory fails first — repeating a question five minutes later, forgetting a conversation from the morning. Language, spatial orientation and judgment follow as plaques and tangles spread outward through the cortex.
Survival after diagnosis averages four to eight years, though some people live with it for twenty. The newer anti-amyloid antibodies, lecanemab and donanemab, slow cognitive decline by a modest margin — measured in fractions of a point on standard rating scales — and carry a real risk of brain swelling and micro-bleeds, which is why patients on them need periodic scans.
2. Parkinson’s Disease
The classic four signs are a resting tremor, muscle rigidity, slowed movement and postural instability, but the disease usually starts elsewhere. Loss of smell, chronic constipation and REM sleep behavior disorder — acting out dreams — can precede the first tremor by a decade or more.
Levodopa, in use since the late 1960s, remains the most effective treatment. It works well for years, then motor fluctuations and dyskinesias creep in. Deep brain stimulation helps selected patients with those fluctuations. Roughly 10–15% of cases have a clear genetic driver, with LRRK2 and GBA variants among the most studied.
3. Lewy Body Dementia
Lewy body dementia shares its culprit protein with Parkinson’s, and the two conditions sit on a spectrum. The practical distinction is timing: if dementia appears within a year of motor symptoms, it’s classified as Lewy body dementia; if someone has had Parkinson’s for years before cognition slips, it’s Parkinson’s disease dementia.
Its signature features are fluctuating alertness, detailed visual hallucinations and a striking sensitivity to antipsychotic drugs — a single dose of haloperidol can leave a patient rigid and barely responsive. Families often describe good days and bad days that differ enormously.
4. Frontotemporal Dementia
This is the most common dementia in people under 60, and the one most often mistaken for something else. Behavioral variant FTD shows up as personality change: a previously tactful adult making blunt comments, losing interest in hobbies, eating compulsively, or behaving impulsively with money. Language variants erode word-finding and comprehension while memory stays intact.
Up to 40% of cases run in families, with mutations in MAPT, GRN and C9orf72 accounting for many of them. Median survival is seven to thirteen years from symptom onset. Because onset is often in the 50s, patients are frequently misdiagnosed with depression, midlife crisis or a psychiatric disorder first.
5. Amyotrophic Lateral Sclerosis (ALS)
ALS attacks upper and lower motor neurons, producing progressive weakness, muscle wasting, cramps and spasticity. Roughly 31,000 Americans are living with it and about 5,000 are diagnosed each year. Most people die of respiratory failure within three to five years, though a minority follow a far slower course.
It isn’t purely a motor disease. Up to half of patients show some cognitive or behavioral change, and about 15% develop frank frontotemporal dementia — the same C9orf72 mutation causes both. Treatment options remain limited: riluzole, edaravone, and tofersen for the small subset with SOD1 mutations.
6. Huntington’s Disease
Huntington’s is inherited in an autosomal dominant pattern, meaning a child of an affected parent has a 50% chance of carrying it, and carriers almost always develop symptoms if the CAG repeat expansion is long enough. Around 30,000 Americans have symptomatic disease and another 200,000 are at risk.
Chorea — involuntary, dance-like movements — is the most visible sign, but cognitive decline and psychiatric symptoms (irritability, apathy, depression) often cause more day-to-day difficulty. Onset typically falls between 30 and 50. Tetrabenazine and deutetrabenazine reduce chorea; nothing yet slows the disease itself, and gene-silencing trials have produced disappointing results so far.
7. Multiple Sclerosis
MS is technically immune-mediated rather than purely degenerative, but the progressive stage is driven by axon loss, so it belongs on this list. Roughly 85% of patients start with relapsing-remitting disease, where episodes of optic neuritis, numbness, balance problems or bladder issues are followed by recovery.
More than twenty disease-modifying therapies now exist, and early, aggressive treatment has changed the trajectory for many people. Research into the underlying mechanisms keeps taking unexpected turns — studies of yaks and their unusual biology have offered clues about how the nervous system might repair myelin.
How Neurologists Tell Them Apart
There is no single blood test that answers the question. Diagnosis is built from history, examination, imaging and, increasingly, fluid biomarkers.
- MRI — shows atrophy patterns, white matter lesions in MS, and midbrain changes in Parkinson’s.
- PET imaging — amyloid and tau tracers can confirm Alzheimer’s pathology years before symptoms.
- Lumbar puncture — cerebrospinal fluid levels of amyloid, tau and alpha-synuclein support a diagnosis.
- Blood biomarkers — p-tau217 tests now rival spinal fluid for detecting Alzheimer’s pathology.
- EMG and nerve conduction studies — the standard for confirming ALS.
- Genetic testing — essential for Huntington’s, and useful in familial ALS and FTD.
Understanding which scan reveals what makes the diagnostic process less mysterious — this plain-language guide to medical imaging covers the differences between MRI, CT and PET in useful detail.
Where These Diseases Overlap
Textbook categories are cleaner than real patients. Alpha-synuclein diseases blur into one another, ALS and FTD share genetics, and Alzheimer’s pathology turns up in a third of Parkinson’s brains at autopsy.
Immunology is another area of surprise. Researchers once assumed every neurodegenerative process involved runaway inflammation, yet post-mortem work has shown that in some fatal brain conditions the immune response is strangely muted rather than overactive — a finding that reframes how scientists think about treating them. Age remains the single strongest risk factor across the entire group.
What Actually Helps, Starting Today
No diet prevents Alzheimer’s, and anyone selling you a supplement that does is guessing. What the evidence does support is vascular health. Blood pressure control matters — a systolic target under 120 reduced new mild cognitive impairment in the SPRINT trial. Smoking cessation, treating hearing loss, and staying socially engaged all show up repeatedly in prevention research, alongside the practical habits in this roundup of straightforward health and longevity tips.
Exercise has the strongest supporting data of any lifestyle intervention. Aerobic activity improves cardiovascular fitness and mood; resistance work protects muscle mass, bone density and the strength needed to stay mobile as the disease progresses. For anyone facing a movement disorder, the principles in this article on strength training for stroke recovery and healthy aging translate well.
Two practical steps are worth more than any supplement. First, get a proper evaluation from a neurologist or a memory clinic rather than accepting a vague diagnosis — the difference between FTD and early-onset Alzheimer’s changes everything about planning. Second, ask about clinical trials. Sites enroll constantly, and participants often receive specialist monitoring that is difficult to access otherwise. Caregiver support groups, occupational therapy home assessments and advance care planning belong in the conversation early, while the person with the diagnosis can still shape the decisions.
